The frequency of Ras mutations in cancer
By I. Prior, Fiona E. Hood, J. Hartley. Cancer Research, 2020
805 citations recorded by the source corpus.
Ras is frequently mutated in cancer, however, there is a lack of consensus in the literature regarding the cancer mutation frequency of Ras, with quoted values varying from 10%–30%. This variability is at least in part due to the selective aggregation of data from different databases and the dominant influence of particular cancer types and particular Ras isoforms within these datasets. To provide a more definitive figure for Ras mutation frequency in cancer, we cross-referenced the data in all major publicly accessible cancer mutation databases to determine reliable mutation frequency values for each Ras isoform in all major cancer types. These percentages were then applied to current U.S. cancer incidence statistics to estimate the number of new patients each year that have Ras-mutant cancers. We find that approximately 19% of patients with cancer harbor Ras mutations, equivalent to approximately 3.4 million new cases per year worldwide. We discuss the Ras isoform and mutation-specific trends evident within the datasets that are relevant to current Ras-targeted therapies.
Subfields: Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/f2f6fe28770faf09459f36f9b562791966d44e73
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies (2024, background): “198,199 41 Inhibiting RAS or the downstream RAF/MEK/MAPK axis can reverse the erastin or RSL3-induced selective cytotoxicity in engineered RAS-mutant tumor cells, possibly because mutant RAS signaling enhances the cellular basal iron by modulating the expression of iron metabolism-related genes.”